Antibody response to respiratory syncytial virus infection in children

Susanna Esposito, Elisa Scarselli, Mara Lelii, Alessia Scala, Alessandra Vitelli, Stefania Capone, Marco Fornili, Elia Biganzoli, Annalisa Orenti, Alfredo Nicosia, Riccardo Cortese, Nicola Principi

Research output: Contribution to journalArticle

Abstract

The development of a safe and effective respiratory syncytial virus (RSV) vaccine might be facilitated by knowledge of the natural immune response to this virus. The aims of this study were to evaluate the neutralizing antibody response of a cohort of healthy children 6 copies/mL (p = 0.03), and those with LRTIs during the study period (p = 0.03), but it was not associated with the immune response (p = 0.41). In conclusion, natural RSV infection seems to evoke a low immune response in younger children. To be effective in this infant population, which is at highest risk of developing severe LRTIs, vaccines must be able to induce in the first months of life a stronger immune response than that produced by the natural infection.

Original languageEnglish
Pages (from-to)1-7
Number of pages7
JournalHuman Vaccines and Immunotherapeutics
DOIs
Publication statusAccepted/In press - Apr 5 2016

Fingerprint

Respiratory Syncytial Virus Infections
Antibody Formation
Respiratory Syncytial Virus Vaccines
Neutralizing Antibodies
Vaccines
Viruses
Infection
Population

Keywords

  • neutralizing antibody
  • pediatric infectious diseases
  • respiratory tract infection
  • RSV
  • RSV vaccine

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology

Cite this

Esposito, S., Scarselli, E., Lelii, M., Scala, A., Vitelli, A., Capone, S., ... Principi, N. (Accepted/In press). Antibody response to respiratory syncytial virus infection in children. Human Vaccines and Immunotherapeutics, 1-7. https://doi.org/10.1080/21645515.2016.1145847

Antibody response to respiratory syncytial virus infection in children. / Esposito, Susanna; Scarselli, Elisa; Lelii, Mara; Scala, Alessia; Vitelli, Alessandra; Capone, Stefania; Fornili, Marco; Biganzoli, Elia; Orenti, Annalisa; Nicosia, Alfredo; Cortese, Riccardo; Principi, Nicola.

In: Human Vaccines and Immunotherapeutics, 05.04.2016, p. 1-7.

Research output: Contribution to journalArticle

Esposito, S, Scarselli, E, Lelii, M, Scala, A, Vitelli, A, Capone, S, Fornili, M, Biganzoli, E, Orenti, A, Nicosia, A, Cortese, R & Principi, N 2016, 'Antibody response to respiratory syncytial virus infection in children', Human Vaccines and Immunotherapeutics, pp. 1-7. https://doi.org/10.1080/21645515.2016.1145847
Esposito, Susanna ; Scarselli, Elisa ; Lelii, Mara ; Scala, Alessia ; Vitelli, Alessandra ; Capone, Stefania ; Fornili, Marco ; Biganzoli, Elia ; Orenti, Annalisa ; Nicosia, Alfredo ; Cortese, Riccardo ; Principi, Nicola. / Antibody response to respiratory syncytial virus infection in children. In: Human Vaccines and Immunotherapeutics. 2016 ; pp. 1-7.
@article{61c9f6a3bd454258a0ff4f8ef8d7eb18,
title = "Antibody response to respiratory syncytial virus infection in children",
abstract = "The development of a safe and effective respiratory syncytial virus (RSV) vaccine might be facilitated by knowledge of the natural immune response to this virus. The aims of this study were to evaluate the neutralizing antibody response of a cohort of healthy children 6 copies/mL (p = 0.03), and those with LRTIs during the study period (p = 0.03), but it was not associated with the immune response (p = 0.41). In conclusion, natural RSV infection seems to evoke a low immune response in younger children. To be effective in this infant population, which is at highest risk of developing severe LRTIs, vaccines must be able to induce in the first months of life a stronger immune response than that produced by the natural infection.",
keywords = "neutralizing antibody, pediatric infectious diseases, respiratory tract infection, RSV, RSV vaccine",
author = "Susanna Esposito and Elisa Scarselli and Mara Lelii and Alessia Scala and Alessandra Vitelli and Stefania Capone and Marco Fornili and Elia Biganzoli and Annalisa Orenti and Alfredo Nicosia and Riccardo Cortese and Nicola Principi",
year = "2016",
month = "4",
day = "5",
doi = "10.1080/21645515.2016.1145847",
language = "English",
pages = "1--7",
journal = "Human Vaccines and Immunotherapeutics",
issn = "2164-5515",
publisher = "Taylor and Francis Inc.",

}

TY - JOUR

T1 - Antibody response to respiratory syncytial virus infection in children

AU - Esposito, Susanna

AU - Scarselli, Elisa

AU - Lelii, Mara

AU - Scala, Alessia

AU - Vitelli, Alessandra

AU - Capone, Stefania

AU - Fornili, Marco

AU - Biganzoli, Elia

AU - Orenti, Annalisa

AU - Nicosia, Alfredo

AU - Cortese, Riccardo

AU - Principi, Nicola

PY - 2016/4/5

Y1 - 2016/4/5

N2 - The development of a safe and effective respiratory syncytial virus (RSV) vaccine might be facilitated by knowledge of the natural immune response to this virus. The aims of this study were to evaluate the neutralizing antibody response of a cohort of healthy children 6 copies/mL (p = 0.03), and those with LRTIs during the study period (p = 0.03), but it was not associated with the immune response (p = 0.41). In conclusion, natural RSV infection seems to evoke a low immune response in younger children. To be effective in this infant population, which is at highest risk of developing severe LRTIs, vaccines must be able to induce in the first months of life a stronger immune response than that produced by the natural infection.

AB - The development of a safe and effective respiratory syncytial virus (RSV) vaccine might be facilitated by knowledge of the natural immune response to this virus. The aims of this study were to evaluate the neutralizing antibody response of a cohort of healthy children 6 copies/mL (p = 0.03), and those with LRTIs during the study period (p = 0.03), but it was not associated with the immune response (p = 0.41). In conclusion, natural RSV infection seems to evoke a low immune response in younger children. To be effective in this infant population, which is at highest risk of developing severe LRTIs, vaccines must be able to induce in the first months of life a stronger immune response than that produced by the natural infection.

KW - neutralizing antibody

KW - pediatric infectious diseases

KW - respiratory tract infection

KW - RSV

KW - RSV vaccine

UR - http://www.scopus.com/inward/record.url?scp=84963615982&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963615982&partnerID=8YFLogxK

U2 - 10.1080/21645515.2016.1145847

DO - 10.1080/21645515.2016.1145847

M3 - Article

SP - 1

EP - 7

JO - Human Vaccines and Immunotherapeutics

JF - Human Vaccines and Immunotherapeutics

SN - 2164-5515

ER -